Mr. Michael Tan reports

NUMINUS WELLNESS INC. ANNOUNCES STRATEGIC WIND-DOWN OF NON-OPERATING SUBSIDIARIES

Numinus Wellness Inc.'s board of directors has approved the wind-down of certain non-operating subsidiaries as part of the company's efforts to simplify its corporate structure and concentrate resources on its core business areas. This initiative is intended to enhance operational efficiency and financial sustainability.

The subsidiaries affected and their respective wind-down methods are as follows:

• Mindspace Services Inc. (Canada) -- bankruptcy;
• Neurology Centre of Toronto Inc. (Ontario) -- bankruptcy;
• Numinus Bioscience Inc. (British Columbia) -- bankruptcy;
• Salvation Bioscience Inc. (Canada) -- bankruptcy;
• Numinus Health Corp. (British Columbia) -- bankruptcy.

These actions do not affect Numinus's ability to continue operations. The company remains focused on its research and training businesses, which form the foundation of its mission to advance mental health solutions and psychedelic-assisted therapies. By streamlining its corporate structure, Numinus is ensuring a more sustainable and efficient path forward.

"This initiative allows us to allocate resources more effectively and maintain focus on our core operations," said Michael Tan, chief executive officer of Numinus.

The company has engaged Dodick Landau Inc. to oversee the bankruptcy proceedings. Additionally, Numinus will ensure that all required Canada Revenue Agency filings for the affected entities are completed prior to the finalization of the wind-down process.

This announcement is being made in accordance with Toronto Stock Exchange and securities disclosure requirements. Further details regarding this matter will be included in the company's forthcoming material change report, to be filed within 10 days on SEDAR+.

The company is continuing to prepare its annual and interim financial statements and management's discussion and analysis, which will be filed as soon as possible.

About Numinus Wellness Inc.

Numinus helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model -- technology-driven clinic support, clinical trial research and comprehensive practitioner training -- is at the forefront of a transformation aimed at healing rather than managing symptoms of depression, anxiety, trauma, pain and substance use. At Numinus, it is leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

We seek Safe Harbor.